• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

Nonsteroidal antiinflammatory drugs: benefit/risk evaluation in rheumatic diseases.

作者信息

Fenner H

机构信息

Clinical Research Department, F. Hoffman-La Roche Ltd., Basel, Switzerland.

出版信息

J Rheumatol Suppl. 1992 Jan;32:98-9.

PMID:1613741
Abstract

Side effects of nonsteroidal antiinflammatory drug (NSAID) therapy are attributed to direct damage by the acidic compounds and to the secondary effects of prostaglandin inhibition. In general, gastrointestinal, skin and central nervous system effects predominate, followed by general adverse hepatic and renal events. Advanced age, female gender, history of gastrointestinal disorders and renal impairment increase the risk of NSAID induced side effects. Pharmacologic modifications that may help minimize side effects include lowered cyclooxygenase inhibitor activity, more stable plasma/tissue concentrations, decreased lipophilicity, avoidance of biliary excretion and renal excretion in inactive form. Prescribing NSAID according to their differing pharmacokinetic profiles may help maximize clinical efficacy and reduce side effects.

摘要

相似文献

1
Nonsteroidal antiinflammatory drugs: benefit/risk evaluation in rheumatic diseases.
J Rheumatol Suppl. 1992 Jan;32:98-9.
2
[Preferential COX-2 inhibition: its clinical relevance for gastrointestinal non-steroidal anti-inflammatory rheumatic drug toxicity].[选择性环氧化酶-2抑制作用:其对胃肠道非甾体抗炎性风湿药物毒性的临床意义]
Z Gastroenterol. 1999 Jan;37(1):45-58.
3
The multisystem adverse effects of NSAID therapy.非甾体抗炎药治疗的多系统不良反应。
J Am Osteopath Assoc. 1999 Nov;99(11 Suppl):S1-7.
4
[Gastrointestinal side effects of non-steroidal anti-inflammatory drugs in high-risk patients--role of selective cyclooxygenase inhibitors].[高危患者中非甾体抗炎药的胃肠道副作用——选择性环氧化酶抑制剂的作用]
Orv Hetil. 2001 Sep 2;142(35):1899-905.
5
[NSAID therapy. Gastrointestinal risks of classic NSAID are underestimated].[非甾体抗炎药治疗。传统非甾体抗炎药的胃肠道风险被低估了]
MMW Fortschr Med. 2010 May 20;152(20):46-7.
6
Gastrointestinal health care resource use and costs associated with nonsteroidal antiinflammatory drugs versus acetaminophen: retrospective cohort study of an elderly population.非甾体抗炎药与对乙酰氨基酚相关的胃肠道医疗资源使用及成本:老年人群的回顾性队列研究
Arthritis Rheum. 2000 Apr;43(4):917-24. doi: 10.1002/1529-0131(200004)43:4<917::AID-ANR25>3.0.CO;2-F.
7
The cost effectiveness of rofecoxib and celecoxib in patients with osteoarthritis or rheumatoid arthritis.罗非昔布和塞来昔布用于骨关节炎或类风湿关节炎患者的成本效益。
Arthritis Rheum. 2003 Jun 15;49(3):283-92. doi: 10.1002/art.11121.
8
[Secondary and primary prophylaxis of gastropathy associated with nonsteroidal antiinflammatory drugs or low-dose-aspirin: a review based on four clinical scenarios].[非甾体类抗炎药或小剂量阿司匹林相关性胃病的二级和一级预防:基于四种临床情况的综述]
Z Gastroenterol. 2003 Aug;41(8):719-28. doi: 10.1055/s-2003-41208.
9
Economic evaluation of nonsteroidal anti-inflammatory drug strategies in rheumatoid arthritis.类风湿关节炎中非甾体抗炎药策略的经济学评估。
Int J Technol Assess Health Care. 2009 Apr;25(2):190-5. doi: 10.1017/S0266462309090242.
10
Non-steroidal antiinflammatory drugs. A review.非甾体抗炎药。综述。
AAOHN J. 1998 May;46(5):253-9; quiz 260-1.

引用本文的文献

1
Systematic review of the cost effectiveness of prophylactic treatments in the prevention of gastropathy in patients with rheumatoid arthritis or osteoarthritis taking non-steroidal anti-inflammatory drugs.对类风湿关节炎或骨关节炎患者服用非甾体抗炎药时预防性治疗预防胃病成本效益的系统评价。
Ann Rheum Dis. 2000 Oct;59(10):753-9. doi: 10.1136/ard.59.10.753.
2
Pharmacoeconomics: where is the link with pharmacokinetics and biopharmaceutics?
Pharm World Sci. 1997 Apr;19(2):73-81. doi: 10.1023/a:1008656303570.
3
Pharmacoeconomics: where is the link with pharmacokinetics and biopharmaceutics?
Eur J Drug Metab Pharmacokinet. 1996 Apr-Jun;21(2):189-200. doi: 10.1007/BF03190269.